1.

肺癌脑转移患者临床试验数据来源

Data sources of clinical trials for lung cancer patients with brain metastasis

Study	Year	Treatment	Outcome	Citation
WBRT: whole brain radiotherapy; EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitor; SRS: stereotactic radiotherapy; ORR: objective response rate; mPFS: median progression-free survival; mOS: median overall survival; DCR: disease control rate; *: subgroup analysis for brain metastasis lung cancer patients.
Clinical trials for patients with brain metastasis
BRAIN	2017	Icotinib vs WBRT	mPFS: 6.8 mo vs 3.4 mo, imPFS: 10.0 mo vs 4.8 mo	[36]
CTONG-0803	2012	Erlotinib	ORR: 58.3%; mPFS: 15.2 mo; imPFS: 10.1 mo;	[15]
Iuchi	2013	Gefitinib	ORR: 87.8%; mPFS: 14.5 mo; mOS: 21.9 mo	[14]
Park	2012	Erlotinib or gefitinib	DCR: 93%; mPFS: 6.6 mo; mOS: 15.9 mo	[13]
William	2016	EGFR-TKI+SRS or WBRT；WBRT+EGFR-TKI；SRS+EGFR-TKI	mOS: 19.4 mo vs 29.9 mo vs 58.4 mo	[43]
William	2017	EGFR-TKI+SRS or WBRT；WBRT+EGFR-TKI；SRS+EGFR-TKI	mOS: 25 mo vs 30 mo vs 46 mo	[42]
BLOOM	2017	AZD3759	1st-line: ORR: 65%, iORR: 83% 2nd line: ORR: 28%	[28]
Subgroup analysis for patients with brain metastasis
ALEX	2017	Alectinib vs crizotinib	mPFS: 34.8 mo vs 10.9 mo, mPFS*: 27.7 mo vs 7.4 mo	[30]
ASCEND-4	2017	Ceritinib vs platinum-based chemotherapy	mPFS: 16.6 mo vs 8.1 mo mPFS*: 10.7 mo vs 6.7 mo	[41]
AURA3	2016	Osimertinib vs platinum-pemetrexed	ORR*: 71% vs 31%, mPFS*: 10.1 mo vs 4.4 mo, imPFS*: 8.5 mo vs 4.2 mo	[39]
FLAURA	2017	Osimertinib vs standard EGFR-TKI	mPFS: 18.9 mo vs 10.2 mo, mPFS*: 15.2 mo vs 9.6 mo	[27]
J-ALEX	2017	Alectinib vs crizotinib	mPFS: 34.1 mo vs 10.2 mo	[29]
LUX-Lung 3 & 6	2015	Afatinib vs cisplatin-based chemotherapy	mPFS*: 8.2 mo vs 5.4 mo, ORR*: 70% vs 20%	[37, 38]
NCT01970865	2018	Lorlatinib	ORR: 90%, ORR*: 66.7%	[31]
NCT01449461	2016	Brigatinib	mPFS: 15.6 mo	[32]
PROFILE 1005 or 1007	2015	Crizotinib	1st line: DCR: 63%, iDCR: 56%, mPFS: 7 mo; 2nd line: DCR: 65%, iDCR: 2%, mPFS: 13.2 mo	[16-18]
PROFILE 1014	2014	Crizotinib vs chemotherapy	ORR: 74% vs 45%, mPFS: 10.9 mo vs 7 mo, ORR*: 77% vs 28%, mPFS*: 9 mo vs 4 mo	[40]
ALTA	2017	Brigatinib	ORR: 54%, mPFS: 12.9 mo	[45]
ASCEND-5	2017	Ceritinib vs chemotherapy	mPFS: 5.4 mo vs 1.6 mo	[46]
NCT02737501	2018	Brigatinib vs crizotinib	ORR: 71% vs 60%, iORR: 78% vs 29%	[47]
NCT01801111	2015	Alectinib	ORR: 50%, mPFS: 8.9 mo	[48]
NCT01871805	2016	Alectinib	ORR: 48%, mPFS: 8.1 mo	[49]
NCT01964157	2017	Ceritinib	ORR: 62%, mPFS: 9.3 mo, mOS: 24 mo	[50]
NCT01336634	2016	Dabrafenib+trametinib	ORR: 63.2%, mPFS: 9.7 mo	[34]